Claim:
Data that came out after the EMA application (ABCLEAR 2, ABCLEAR 3, Brain atrophy TIED to ABCLEAR2/3, ADNI comparisons, prodromal comparisons, etc.) were ALL excluded from the actual regulatory decision.
Accuracy: True
AVXL submitted its Marketing Authorization Application (MAA) for Blarcamesine (ANAVEX®2-73) to the EMA in November 2024, based primarily on Phase 2b/3 trial data (e.g., ANAVEX2-73-AD-004). At the time of filing, certain datasets were incomplete or absent, including full open-label extension (OLE) data (only partial 144-week data was included), ADNI (Alzheimer's Disease Neuroimaging Initiative) comparisons, GWAS (genome-wide association studies), and prodromal-stage analyses. The EMA encouraged filing despite these gaps.
Post-submission data (e.g., long-term benefit analyses announced October 29, 2025; brain atrophy correlations tied to ABCLEAR datasets; full ADNI/prodromal comparisons) emerged during the ~12-month review period but was not fully incorporated or considered in the CHMP's initial assessment leading to the negative trend vote on November 14, 2025. The "regulatory decision" here refers to the CHMP's preliminary negative opinion (formal adoption expected in December 2025), which focused on the original submission's limitations rather than these later datasets.
Nuance: "ABCLEAR" appears to refer to specific biomarker or atrophy-related endpoints (e.g., ABCLEAR 2/3 as post-hoc analyses of trial data). These were generated/analyzed after filing but before the opinion, yet excluded from the core review due to timing and submission constraints.
Claim:
The difference is that with appeal, AVXL CAN use all the aforementioned data which insurmountably improves the strength of the filing, with all that information now able to be officially considered by the CHMP.
Accuracy: True
In re-examination, AVXL plans to submit "relevant biomarker data" (explicitly including the excluded datasets like ABCLEAR, ADNI comparisons, brain atrophy ties, and prodromal analyses) to address CHMP concerns. This data, available by the time of the initial opinion, was not fully weighed in the first review but can now form the "detailed grounds" for re-evaluation by a new set of CHMP reviewers (independent of the original assessment). AVXL and analysts view this as a significant strengthening factor, potentially "insurmountably" improving the case given the data's supportive nature (e.g., long-term benefits vs. natural decline).
Caveat: EMA guidelines strictly state that re-examination grounds must be "based solely on scientific data available at the time of the initial opinion" and cannot introduce entirely novel post-opinion data. However, the datasets in question (post-application but pre-opinion) qualify as "available" and eligible, aligning with AVXL's strategy. No truly "new" data post-December 2025 would be allowed, but this doesn't impact the claim.
Market Data 
Markets 
AI
